Literature DB >> 18163212

Medical consequences of acromegaly: what are the effects of biochemical control?

Annamaria Colao1, Renata S Auriemma, Rosario Pivonello, Mariano Galdiero, Gaetano Lombardi.   

Abstract

This chapter discusses the effects of biochemical control of acromegaly on cardiovascular diseases, metabolic complications, respiratory abnormalities, malignancies and bone alterations. Acromegaly is associated with increased morbidity and mortality for cardiovascular and respiratory complications, whereas neoplasms seem to be a minor cause of increased risk of death. Other associated diseases are osteoarthritis, carpal tunnel syndrome, fatigue, visual abnormalities and reproductive disorders. Acromegaly results in premature death because of prolonged elevation of GH an IGF-I levels, and a strong biochemical control improves well-being and restores life expectancy to normal. The main goals of medical treatment of acromegaly include normalization of biochemical markers of disease activity, improvement in signs and symptoms of the disease, removal or reduction of tumor mass and preservation of pituitary function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18163212     DOI: 10.1007/s11154-007-9062-0

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  45 in total

Review 1.  Cardiovascular function in acromegaly.

Authors:  R N Clayton
Journal:  Endocr Rev       Date:  2003-06       Impact factor: 19.871

2.  Serum lipids in acromegaly.

Authors:  E A Nikkilä; R Pelkonen
Journal:  Metabolism       Date:  1975-07       Impact factor: 8.694

3.  Arrhythmia profile in acromegaly.

Authors:  G Kahaly; K V Olshausen; S Mohr-Kahaly; R Erbel; S Boor; J Beyer; J Meyer
Journal:  Eur Heart J       Date:  1992-01       Impact factor: 29.983

4.  Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.

Authors:  Jens Otto Lunde Jørgensen; Ulla Feldt-Rasmussen; Jan Frystyk; Jian-Wen Chen; Lars Østergård Kristensen; Claus Hagen; Hans Ørskov
Journal:  J Clin Endocrinol Metab       Date:  2005-07-26       Impact factor: 5.958

5.  Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients.

Authors:  S Kasayama; M Otsuki; M Takagi; H Saito; S Sumitani; H Kouhara; M Koga; Y Saitoh; T Ohnishi; N Arita
Journal:  Clin Endocrinol (Oxf)       Date:  2000-05       Impact factor: 3.478

6.  Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.

Authors:  Annamaria Colao; Roberto Attanasio; Rosario Pivonello; Paolo Cappabianca; Luigi M Cavallo; Giovanni Lasio; Alessandro Lodrini; Gaetano Lombardi; Renato Cozzi
Journal:  J Clin Endocrinol Metab       Date:  2005-11-01       Impact factor: 5.958

7.  Early vascular alterations in acromegaly.

Authors:  Gregorio Brevetti; Paolo Marzullo; Antonio Silvestro; Rosario Pivonello; Gabriella Oliva; Carolina di Somma; Gaetano Lombardi; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2002-07       Impact factor: 5.958

8.  The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion.

Authors:  Robert D Murray; Kiwon Kim; Song-Guang Ren; Ian Lewis; Gisbert Weckbecker; Christian Bruns; Shlomo Melmed
Journal:  J Clin Endocrinol Metab       Date:  2004-06       Impact factor: 5.958

9.  Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly.

Authors:  B Merola; A Cittadini; A Colao; D Ferone; S Fazio; D Sabatini; B Biondi; L Saccá; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1993-09       Impact factor: 5.958

10.  Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion.

Authors:  M J Lim; A L Barkan; A J Buda
Journal:  Ann Intern Med       Date:  1992-11-01       Impact factor: 25.391

View more
  8 in total

1.  Clinical features and therapeutic outcomes of patients with acromegaly: single-center experience.

Authors:  T Dusek; D Kastelan; A Melada; M Baretic; T Skoric Polovina; Z Perkovic; Z Giljevic; J Jelcic; J Paladino; I Aganovic; M Korsic
Journal:  J Endocrinol Invest       Date:  2011-07-12       Impact factor: 4.256

2.  N-terminal pro-brain natriuretic peptide in newly diagnosed acromegaly.

Authors:  S Arikan; M Bahceci; A Tuzcu; D Gokalp
Journal:  J Endocrinol Invest       Date:  2010-09       Impact factor: 4.256

3.  Thyroid autoimmune disorders in patients with acromegaly.

Authors:  M Manavela; C Vigovich; K Danilowicz; A Juri; L Miechi; V Fernandez Valoni; O D Bruno
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

4.  Long-term results of fractionated stereotactic radiotherapy as third-line treatment in acromegaly.

Authors:  Alpha M Diallo; Philippe Colin; Claude F Litre; Mamadou M Diallo; Bénédicte Decoudier; Florence Bertoin; Brigitte Higel; Martine Patey; Pascal Rousseaux; Brigitte Delemer
Journal:  Endocrine       Date:  2015-05-09       Impact factor: 3.633

5.  Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study.

Authors:  Emmanuelle Kuhn; Luigi Maione; Amir Bouchachi; Myriam Rozière; Sylvie Salenave; Sylvie Brailly-Tabard; Jacques Young; Peter Kamenicky; Patrick Assayag; Philippe Chanson
Journal:  Eur J Endocrinol       Date:  2015-11       Impact factor: 6.664

6.  The association between biochemical control and cardiovascular risk factors in acromegaly.

Authors:  John D Carmichael; Michael S Broder; Dasha Cherepanov; Eunice Chang; Adam Mamelak; Qayyim Said; Maureen P Neary; Vivien Bonert
Journal:  BMC Endocr Disord       Date:  2017-03-09       Impact factor: 2.763

Review 7.  Acromegaly, inflammation and cardiovascular disease: a review.

Authors:  Thalijn L C Wolters; Mihai G Netea; Niels P Riksen; Adrianus R M M Hermus; Romana T Netea-Maier
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

Review 8.  Implementing a screening program for acromegaly in Latin America: necessity versus feasibility.

Authors:  Karina Danilowicz; Patricia Fainstein Day; Marcos P Manavela; Carlos Javier Herrera; María Laura Deheza; Gabriel Isaac; Ariel Juri; Debora Katz; Oscar D Bruno
Journal:  Pituitary       Date:  2016-08       Impact factor: 4.107

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.